Troglitazone

CHEMBL408 Phase 4 Disetujui Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

441.5 g/mol

LogP

5.1

Phase

4

Troglitazone was the first thiazolidinedione (TZD) PPAR-gamma agonist approved for type 2 diabetes, acting by activating peroxisome proliferator-activated receptor gamma to improve insulin sensitivity in peripheral tissues including muscle, fat, and liver. It was withdrawn from the market due to severe idiosyncratic hepatotoxicity causing liver failure and death, despite its efficacy in reducing hyperglycemia and cardiovascular risk markers. It served as the prototype for subsequent TZDs (rosiglitazone, pioglitazone) with improved safety profiles.

Berat Molekul

441,5000 g/mol

LogP

5,10

TPSA

110,00 Å²

Lipinski RO5

Lulus

Area Terapeutik

Cardiovascular Disease Type 2 Diabetes

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Struktur 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

Cc1c(C)c2c(c(C)c1O)CCC(C)(COc1ccc(CC3SC(=O)NC3=O)cc1)O2

InChI

InChI=1S/C24H27NO5S/c1-13-14(2)21-18(15(3)20(13)26)9-10-24(4,30-21)12-29-17-7-5-16(6-8-17)11-19-22(27)25-23(28)31-19/h5-8,19,26H,9-12H2,1-4H3,(H,25,27,28)

Molecular Formula

C24H27NO5S

HBD / HBA

2 / 6

Ikatan yang Dapat Dirotasi

5

Atom Berat

31

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Pertanyaan yang Sering Diajukan

Troglitazone was the first thiazolidinedione (TZD) PPAR-gamma agonist approved for type 2 diabetes, acting by activating peroxisome proliferator-activated receptor gamma to improve insulin sensitivity in peripheral tissues including muscle, fat, and liver. It was withdrawn from the market due to severe idiosyncratic hepatotoxicity causing liver failure and death, despite its efficacy in reducing hyperglycemia and cardiovascular risk markers. It served as the prototype for subsequent TZDs (rosiglitazone, pioglitazone) with improved safety profiles.

Yes, Troglitazone is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL408. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 5591. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Mencari informasi yang ramah bagi pasien?

Troglitazone di PillFYI

Struktur

Data Cepat

Rumus: C24H27NO5S

Tautan Eksternal

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Penyangkalan Medis

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.